Angioimmunoblastic Lymphadenopathy With Dysproteinemia - 29 Studies Found
| Completed |
: Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma :
|
| Terminated |
: 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma :
|
| Completed |
: Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma :
|
| Recruiting |
: A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) :
: Drug: Brentuximab vedotin study drug given intravenously to determine efficacy in study diseases |
| Completed |
: 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma :
|
| Recruiting |
: Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma :
|
| Terminated |
: Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma :
: 2004-10-06 : Drug: bortezomib + ganciclovir Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. P |
| Completed |
: Combination Chemotherapy in Treating Older Patients With Non-Hodgkin's Lymphoma : Lymphoma : 2002-06-06 :
|
| Completed |
: Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer :
: |